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DOI:http://dx.doi.org/10.4314/njp.v40i1,3 Abstract The Global polio eradica-
tion initiative was launched in 1988 
by the international community. 
Since then, tremendous progress has 
been made (99%). However, the last 
1% of the journey has experienced 
several setbacks and rate of progress 
has slowed down in the last few 
years. Nigeria is one of the remain-
ing 3 endemic countries in the world 
that has never interrupted the trans-
mission of the poliovirus compared 
to more than 125 countries in 1988. 
What are the prospects and chal-
lenges to polio eradication in Nige-
ria? This paper discusses these and 
other relevant issues regarding po-





Polio or poliomyelitis is an acute viral disease character-
ized by inflammation of the nerve cells of the brain stem 
and the spinal cord. The disease is caused by a virus 
called Poliovirus. It belongs to the genus, Enterovirus 
and the family, Picornaviridae. Viruses in this family are 
small in size with single stranded RNA. There are 3 se-
rotypes: types 1, 2 and 3. Type 1 is the commonest and 




Polio cases drastically reduced by more than 99%2 from 
an estimated 350,000 in 1988 to 1,352 reported cases in 
20101. The number of endemic countries has reduced 
from 125 in 1988 to 3 in 2012. However, in 2009-2010, 
23 previously polio-free countries were re-infected from 
importations3. Tables 1a and 1b show the trend of re-




Table 1a: Reported wild poliovirus (WPV) cases,* by type (WPV1 or WPV3) and category of polio-affected country — world-
wide, January–March 2010, 2011 and 20123,4. 
 January-March 2010 January–March 2011 January–March 2012 
Category/Country† WPV1 WPV3 All WPV  WPV1 WPV3 All WPV  WPV1 WPV3 All WPV  
Polio-endemic countries 7 33 40 35 2 37 40 9 49 
Afghanistan 1 6 7 1 — 1 6 — 6 
India 3 16 19 1 — 1 — — — 
Nigeria --- 2 2 6 2 8 21 7 28 
Pakistan 3 9 12 27 — 27 13 2§ 15 
Countries with reestab-
lished transmission 1 7 8 77 3 80 3 0 3 
Angola 1 --- 1 2 — 2 — — — 
Chad --- 7 7 33 3 36 3 — 3 
Democratic Republic of 
the Congo --- --- --- 42 — 42 — — — 
Total** 16 80 96 224 10 234 86 16 104 
* Case data reported to the World Health Organization as of May 15, 2012, by date of onset. 
† Country category based on Global Polio Eradication Initiative 2010–2012 Strategic Plan 
§ Includes one mixed WPV1/WPV3. 
**Countries affected by outbreaks are excluded in th s able 
Table 1b: Reported wild poliovirus (WPV) cases,* by type (WPV1 or WPV3) and category of polio-affected  
country — worldwide, 2010–20113,4 
 Total 2010 Total 2011 
Category/Country† WPV1 WPV3 All WPV WPV1 WPV3 All WPV 
Polio-endemic countries 163 69 232 324 17 341 
Afghanistan 17 8 25 80 — 80 
India 18 24 42 1 — 1 
Nigeria 8 13 21 47 15 62 
Pakistan 120 24 144 196 2 198 
Countries with reestablished trans-
mission 144 15 159 227 3 230 
Angola 33 --- 33 5 — 5 
Chad 11 15 26 129 3 132 
Democratic Republic of the 
Congo 100 --- 100 93 — 93 
Total** 614 168 782 1102 40 1142 
**Countries affected by outbreaks are excluded in th s able 
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2 6 --- --- 1.0--2.7 83¶¶ 2.5 yrs January 20, 2011 
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2 5 6 --- 0.7--2.8 26 2.6 yrs March 22, 2011 
Abbreviations: cVDPV = circulating VDPV; DRC = Democratic Republic of Congo; iVDPV = immunodeficiency-associated VDPV; aVDPV = 
ambiguous VDPV; OPV = oral poliovirus vaccine; IPV = inactivated poliovirus vaccine; AFP = acute flaccid paralysis. 
* Total years detected and cumulative totals for previously reported cVDPV outbreaks (DRC, Ethiopia, and Nigeria). 
† Outbreaks list total cVDPV cases. Some VDPV case isolates from outbreak periods might be listed as aVDPVs. 
§ Total cases for VDPV-positive specimens from AFP cases and total VDPV-positive samples for environmetal (sewage) samples. 
¶ Based on 2009 data from the World Health Organization (WHO) Vaccine Preventable Diseases Monitoring System (2010 global summary) and 
WHO-UNICEF coverage estimates, available at http://www.who.int/immunization_monitoring/en/globalsummary/countryprofileselect.cfm . 
National data might not reflect weaknesses at subnational levels. 
** Duration of cVDPV circulation was estimated from extent of VP1 nucleotide divergence from the corresponding Sabin OPV strain; duration of 
iVDPV replication was estimated from clinical record by assuming that exposure was from initial receipt of OPV; duration of aVDPV replication 
was estimated from sequence data. 
†† Most cVDPV isolates from Afghanistan, Chad, DRC, Ethiopia, Niger, Nigeria, and Somalia were vaccine/nonvaccine recombinants. 
§§ Three cases from 2009 are not included in the count because they had <10 nucleotide substitutions in VP1 and the new definition was not yet 
implemented. 
¶¶ Routine trivalent OPV coverage was 14% among case-p tients. 
*** Importations from Nigerian cVDPV outbreak. One imported VDPV from Niger had been previously incorrectly assigned to be from Guinea. 
††† Previously reported outbreak. Additional information available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5836a3.htm.  
§§§ cVDPVs clustered in Uttar Pradesh and Bihar, where routine coverage with trivalent OPV was ~50%. 
¶¶¶ Previously reported outbreak. Additional information available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5836a3.htm.  
**** Count does not include 29 cases with <10 nucleotide substitutions in VP1 detected before 2010.  
Table 2 shows the trend of vaccine derived polioviruses worldwide from July 2009 to March 20115. 
   16 
The global estimation of routine trivalent OPV (tOPV) 
vaccination coverage (3 doses of tOPV by 12 months) 
by the end of 2010 was 86%. The WHO Regional cover-
ages were 79%, 93%, 96% and 77% for African, the  
Americas, European and West Pacific, and South-East 
Asian Regions respectively6. Some indicators of success 
of the global polio eradication efforts are shown in  
table 3 1. 
Table 3: Selected indicators of the success of the Global Polio Eradication Initiative 
Parameter 1988 2000 2006 2009 
No. of new cases per year 300 000 719 1997 1606 
No. of endemic countries >125 20 4 4 
No. of endemic WHO Regions 6 3 3 3 
No. of circulating wild WPV serotypes 3 2 2 2 
No. of remaining WPV genotypes# WPV1: 20 WPV1: 9 WPV1: 2 WPV1: 2 
  WPV2: 5 WPV2: 0 WPV2: 0 WPV2: 0 
  WPV3: 17 WPV3: 7 WPV3:2 WPV3: 2 
WPV, Wild-type poliovirus. 
# A genotype is a group of genetically closely related poliovirus strains (difference in capsid protein VP1 coding 
sequence >15%) that are considered to have epidemiological linkage with each other1. 
Transmission 
 
Polioviruses are mainly transmitted through the faeco-
oral route (via stool contaminated food and water) and 
also by person to person contact. They are acid resstant 
and therefore able to travel safely through the stomach 
to settle in the gut where they replicate. Therefore trans-
mission occurs most in areas with poor personal and 
environmental hygiene. Polioviruses can survive for
weeks in water and sewage. Poliomyelitis is highly in-
fectious and transmission is expected to occur in almost 
100% of susceptible children and more than 90% of 
susceptible adult household contacts. In general, tr ns-
mission is higher in developing countries. Additionally, 
other factors that determine the ease and speed of spread 
include population density and rate of contact7. 
 
From the gut the viruses reach the central nervous sys-
tem through the blood stream to cause disease. The incu-
bation period is 7-14 days (4-35 days). Polio can be 
symptomatic (4-8%) or asymptomatic (~95%); paralytic 
or non-paralytic (99%)1. On the average, only 1 in 200 
infections will result in acute flaccid paralysis (AFP). 




The symptoms include fever, headache, vomiting, fa-
tigue, neck and back stiffness and muscle pains. Other 
clinical features are paralysis of the limbs and respira-
tory muscles, respiratory failure, swallowing difficulty, 
urinary retention, constipation, diarrhoea and abnormal 
sensations (but not loss of sensation). Severity increases 
with increasing age of infection. Only about 0.1-2% of 
infected people have paralytic polio out of which 5-10% 
die of respiratory failure. Recovery from an infection 





Polio has no cure: clinical cases can only be managed 
with supportive care. Therefore, prevention is the main-
stay of management of polio. Apart from improvement 
in hygiene and sanitation standards, vaccination is the 
primary mode of prevention. Primary and booster doses 
of polio vaccine protects most vaccinees for life. 
 
Two vaccines are currently available namely the live 
attenuated Oral Polio Vaccine (OPV), developed by 
Albert Sabin; and the Inactivated (killed) Polio Vaccine 
(IPV) developed by Jonas Salk. Both vaccines are triva-
lent, though recently, bivalent (bOPV) and monovalent 
(mOPV) vaccines have been produced for data-driven 
supplementary immunization activities (SIAs) in some 
endemic countries.  
 
Although OPV is safe, rare adverse event could occure 
and Vaccine associated paralytic polio (VAPP) is one f 
the most important of these rare adverse events. While 
OPV virus has the potential to revert to a live virus that 
is capable of causing paralysis, IPV cannot cause polio. 
The vaccine associated paralysis is caused by mutation 
or reversion of the Sabin virus to neurovirulence. Such 
circulating vaccine derived polio viruses (cVDPVs) 
therefore can result in polio cases and paralysis similar 
to that caused by wild polio viruses (WPVs). Vaccine 
associated paralytic polio occurs in both vaccinees and 
their unimmunized contacts7. Although wild type 2 polio 
virus has been eliminated since 19991,2,7, type 2 
cVDPVs are still being reported in some endemic coun-
tries. 
 
In a few individuals with primary B-cell immunodefi-
ciency, there is chronic shedding of the Sabin virus with 
increased neurovirulence. Such viruses are called immu-
nodeficiency-associated vaccine derived polioviruses 
(iVDPV). These are not known to occur in HIV infec-
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Definitions 
 
The following definitions were given by the Dahlem 
Workshop on Disease Eradication in 1997 and published 
by the Centers for disease control and prevention (CDC) 
in 19999: 
• Control: The reduction of disease incidence, preva-
lence, morbidity or mortality to a locally acceptable 
level as a result of deliberate efforts; continued in-
tervention measures are required to maintain the 
reduction. Example: diarrhoeal diseases. 
• Elimination of disease: Reduction to zero of the 
incidence of a specified disease in a defined geo-
graphical area as a result of deliberate efforts; con-
tinued intervention measures are required. Example: 
neonatal tetanus. 
• Elimination of infections: Reduction to zero of the 
incidence of infection caused by a specific agent in 
a defined geographical area as a result of deliberate 
efforts; continued measures to prevent re-
establishment of transmission are required. Exam-
ple: measles, poliomyelitis. 
• Eradication: Permanent reduction to zero of the 
worldwide incidence of infection caused by a spe-
cific agent as a result of deliberate efforts; interven-
tion measures are no longer needed. Example: 
smallpox. 
• Extinction: The specific infectious agent no longer 
exists in nature or in the laboratory. Example: none. 
 
However, there are several other definitions of elimina-
tion and eradication ranging from geographically limited 
definitions to global definitions10.  
 
The ultimate aims of public health are disease control, 
elimination and eradication. The basic question is when 
these aims will be achieved. 
 
Why is polio eradicable? 
 
Polio is considered eradicable because: 
• Man is the only reservoir/host. 
• A long term carrier state is not known to occur11. 
• Effective and cheap vaccine is universally available 
(OPV). 
• The vaccine (OPV) is easy to administer on mass 
basis. 
• The polio vaccine is relatively stable. 
 
Direct and Indirect effect of OPV (Herd effects) 
 
When adequate number of doses of OPV are adminis-
tered to a population at risk, the immunity so conferred 
interrupts transmission in that population. This is known 
as the indirect effect of the vaccine, such that any sus-
ceptible individual in that community will no longer be 
exposed to the virus and so is protected, though non-
immune (herd protection). Secondly, vaccinated indi-




individuals thereby conferring immunity on them.  
This is the direct effect of the vaccine (herd immunity)
12. These herd effects result in a population immunity 
that is higher than the sum of the individual immunity of 
the vaccinated individuals in the community. 
 
How synchronized OPV mass campaigns work 
 
Simultaneous administration of OPV within a short pe-
riod interrupts the transmission of wild polio virus by 
displacing it from the gut. The effect is enhanced by a 
100% vaccine coverage of the population at risk 
(children less than 5 years). The result is abrupt interrup-
tion of WPV transmission in the community11. 
 
Global Polio Eradication Initiative (GPEI) 
 
The Global polio eradication initiative was launched in 
1988. It was made up delegates from 166 member states 
who adopted a resolution to eradicate polio world-wi e. 
It was primarily led by the World Health Organization 
(WHO), the Rotary International, the United States Cen-
ters for Disease Control and Prevention (CDC), and the 
United Nations Children’s Fund (UNICEF). 
 
The objectives of the GPEI include7, 13: 
• Interruption of wild polio virus 
• Certification of global polio eradication 
• Contribution to health system development and 
strengthening of routine immunization surveillance 
for communicable diseases in a systematic way. 
 
The GPEI has four major strategies1 for countries af-
fected or at risk of re-infection namely: 
• High routine infant immunization coverage with 4 
doses of OPV in the first year of life  
• Supplementary immunization activities for all under 
five children 
• Optimum surveillance for WPV through reporting 
and laboratory testing of all AFP cases in children 
less than 15 years. 
• Targeted (data-driven) “mop-up” campaigns once 
WPV is limited to specific focal areas. 
 
GPEI Strategic plan 2010-2012 
 
In May 2008, the 61st World Health Assembly called for 
a new one-year programme of work to replace the earlier 
multi-year strategic plan and subsequently, the 2009 
Programme of work was developed. Following the im-
plementation of the 2009 GPEI programme of work, a 
strategic plan was developed based on lessons learned 
from 20 years of experience in polio eradication and 
implementation of the 2009 programme of work. This 
new plan is to be implemented from 2010-2012 with 
definite milestones set (Table 4). The progress is to be 
internationally analyzed and graded by experts2. 
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* validated when six months without a case genetically linked to a 2009 importation (i.e. by end-2010). The target for stopping any 
new outbreaks (i.e. with onset in 2010, 2011 or 2012) will be within six months of the confirmation ofthe index case. 
** validated when 12 months without a case genetically linked to the re-established virus (by end-2011). 
*** validated when 12 months without a case genetically linked to an indigenous virus (by end-2012); the year-to-year change in 
the number of polio cases will be monitored quarterly for each endemic country to guide the assessment of progress towards this 
global milestone. 
† validated when 12 months without a case genetically linked to an indigenous virus (by end-2013). 
†† ‘certification’ will require at least three years of zero polio cases in the presence of appropriate surveillance across an entire  
epidemiologic region2. 
Table 4 : GPEI global milestones 2010-2013 
By mid-2010 By end-2010 By end-2011 By end-2012 By end-2013 
Cessation of all 
polio outbreaks 
with onset in 2009* 




Cessation of all polio trans-
mission in at least two of the 
four endemic countries*** 






Table 5: WHO Regions certified polio free14 
WHO Region Year certified 
The Americans (36 countries) 1994 
Western Pacific (37 countries) 2000* 
European Region (countries) 2002* 
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Abbreviations: mOPV1 = monovalent oral polio vaccine (OPV) type 1; mOPV3 = monovalent OPV type 3; tOPV = trivalent OPV; bOPV = biva-
lent OPV. 
* Mass campaign conducted in a short period (days to weeks) during which a dose of OPV is administered to all children aged <5 years, regardless 
of previous vaccination history. Campaigns can be conducted nationally or in portions of the country. 
Fig 1: Number of laboratory-confirmed cases by wild poliovirus (WPV) type or vaccine-derived poliovirus type 2 (VDPV2) and 
month of onset, type of supplementary immunization activity (SIA),* and type of vaccine administered in Nigeria, January 2009--
*Some countries in these regions have suffered importati ns after 
certification 
However, the current objectives are1 
• Interrupting wild poliovirus transmission in Asia 
• Interrupting wild poliovirus transmission in Africa 
• Enhancing global surveillance and outbreak re-
sponse 
• Strengthening immunization systems 
 
For a WHO region to be certified polio-free, three con-
ditions must be met8:  
• At least 3 years of no polio case due to WPV  
• Disease surveillance efforts in countries must meet 
international standards  
• Each country must show capacity to detect, report 
and respond to “imported” polio cases. 
Since 1988, more than 2 billion children around the
world have been immunized against polio, through the 
unprecedented cooperation of more than 200 countries 
and 20 million volunteers, backed by an international 
investment of more than US$ 5 billion1. 
So far, the following regions have been certified polio-
free: (Table 5) 
 
However, to achieve a global polio-free certification, 
laboratory stocks must be contained and safe manage-









Polio Eradication Trends in Nigeria 
 
In Nigeria, routine surveillance report of AFP cases as-
sociated with faecal excretion of type 2 cVDPV, type 1  
and type 3 WPVs from January 2005 to June 2009 were
studied by Jenkins et al15. It revealed that within the 
study period there were a total of 2,323 cases of type 1 
WPVs, 278 cases of type 2cVDPVs and 1,059 cases of  
type 3 WPVs. There were no significant differences in 
the clinical severity of paralysis caused by these typ s of 
polioviruses.  
 
The progress of polio eradication had been initially 
slow, then checkered and retarded by political and socio-
cultural factors in 2003. Following the resurgence of 
polio in Nigeria in 2003, and subsequent export of he 
virus to 20 other countries, the feasibility of polio eradi-
cation was brought under serious question16. Subse-
quently there was a sudden success leap towards the end 
of 2009 followed by uneven progress till date. Fig 1 
from CDC summarizes the progress between January 
2009 and June 201117. 
 
Table 6 shows the WPV situation worldwide and coun-
try break down as at first week of July 2012. The data 
which was published by the GPEI18 shows that Nigeria 
tops the list and endemic countries contribute more than 
95% of global burden. The total year-to-date WPV in 






Table 6: Wild poliovirus situation worldwide as at 4th July 2012  
  
Countries 
Year-to-date 2012 Year-to-date 2011 
Total in 
 2011*    
Date of most   
 recent case 
 
  WPV1    WPV3     Total     WPV1    WPV3     Total     
Nigeria 40 12 52 12 5 17 62 06-Jun-12 
Afghanistan 10   10 8   8  80  29-May-12 
Pakistan 19 2+1W1W3 22 57 1 58  198  22-May-12 
India       1   1  1  13-Jan-11 
Chad 4   4 82  3  85  132  11-May-12 
DR Congo       60   60  93  20-Dec-11 
Angola      4    4 5 07-Jul-11 
Niger         1 1  5 22-Dec-11 
CAR                    4  08-Dec-11 
China             21 09-Oct-11 
Guinea          1 1  3 03-Aug-11 
Kenya             1 30-Jul-11 
Côte d'Ivoire         11 11 36  24-Jul-11 
Mali          4 4 7  23-Jun-11 
Congo       1   1 1  22-Jan-11 
Gabon       1   1 1 15-Jan-11 
Total 73 14 88 226 26 252 650   
Total in endemic coun-
tries      
69 14 84 78 6 84 341   
Total outbreak     4 0 4 148 20 168 309   
Data in WHO as of 05 Jul 2011 for 2011 data and 03 Jul 2012 for 2012 data1 
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Fig 2a19 highlights the persisting presence of cVDPVs 
in Nigeria. They still constitute a significant proortion 
of the total polio cases. 
Note: The difference between total confirmed polio cases and wild virus con-
firmed polio cases is due to circulating vaccine-derived polio virus. 
 




The eradicability of polio has been a subject of debat  
especially in recent years. Some have called to question  
the rationality or otherwise of the huge sums of fund 
spent globally on the Polio Eradication Initiative (PEI) 
while proponents have advanced their own reasons for 
continuing effort towards the global project. While some 
believe polio is not eradicable, others think that even if 
it is eradicable, it is of little individual benefit20. Yet 
others strongly believe it is not only eradicable, but that 
eradication is in sight. This group also believes it is of 
great public good.  
 
Arguments against eradication 
 
That small pox was successfully eradicated does not 
necessarily imply that other diseases will be eradicated 
also. Epidemiologists have argued that some disease, 
for which global eradication programs have been 
launched in the past, are not eradicable. This is because 
diseases that have non-human reservoirs could be re-
introduced following a presumed eradication. This ap-
plies to malaria and yellow fever whose past global 
eradication programmes have failed20. 
 
Polio vaccine is not as effective as small pox vaccine20 
and after 3 doses of OPV, full protection is not guaran-
teed as vaccines are not equally effective against all 3
strains of the virus7. The live vaccine virus on rare occa-
sions can revert to neuro-virulence and cause disease 
similar to that caused by the wild polio virus. Some have 
described this as using fire to fight fire. These cVDPV 
have been responsible for polio outbreaks in several 
countries7 including Nigeria, Democratic Republic of 
Congo (DRC), Egypt, Haiti and Madagascar5. 
 
Experts argue that since OPV from which these revert d 
strains are derived currently remains the main stayof the  
Polio Eradication Programme (PEP), and realizing that
IPV is too expensive to serve as a substitute in may 
developing countries; “it is clear that poliovirus eradica-
tion using the current affordable strategies is unrealis-
tic” 20. It has been argued that the huge sum of money 
spent on PEP cannot be justified on the basis of disease 
burden. They rather advocate that such funds should be 
invested in developing a cheaper non-live polio vac-
cine20. 
 
The other argument is that polio is largely an asympto-
matic disease and it is estimated that for every single 
case of paralytic polio there are about 200 undetect d 
infections. By the time a response with an SIA is organ-
ized, the disease would have likely spread. Although 
man is the only host, chronic polio virus carriage has 
been demonstrated in small number of patients with B-
cell deficiency in which polio virus has persisted for
many years7. 
 
Additionally and very importantly too, neuro virulent 
polio virus has been synthesized de novo in the labora-
tory21 and this strongly raises a question as to the view 
or concept that the planet can ever be reliably sterilized 
from polio virus. With the advent of bioterriosim coun-
tries cannot ignore the possibility of such an agent being 
used against them by terrorists. According to Grepkin20, 
although the PEP has achieved remarkable success in 
the control of the disease, the continued policy towards 
the present end-point of polio virus eradication, is unat-
tainable. 
 
Arguments for eradication 
 
On the other hand, some experts see polio eradication s 
very feasible from biological point of view. In their 
opinion, since there are effective vaccines, just like in 
the case of small pox, polio can be eradicated. Indeed, 
one of the 3 types of the virus (types) has been eradi-
cated. Additionally 99% reduction in circulation of 
WPV worldwide has already been achieved and many 
countries and some regions have already eliminated th  
virus. The last 1% should be achievable. Only 3 coun-
tries have never interrupted WPV transmission-Nigeria, 
Afghanistan and Pakistan. Even in Nigeria, transmision 
is only limited to Northeast and Northwestern regions f 
the country. All these point to the feasibility of polio 
eradication, not only in Nigeria but globally. Before 
India achieved certification for elimination, it similarly 
had WPV transmission limited to the Uttar Pradesh and 
Bihar states and the Indian Government almost gave up 
on eradication efforts. However further concentration of 
eradication efforts in these areas eventually led to a suc-
cessful interruption of polio transmission. This is in pite 
of lower immune response to tOPV in South East Asia 
than in Africa2. 
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Although polio eradication has been said to divert lim-
ited financial and human resources away from primary 
health care22, a world free of the need for polio vaccine 
would save USD81.5 billion per year in immunization 
costs alone16,23. Additionally, apart from financial sav-
ings and prevention of crippling effects of polio, polio 
eradication also has intangible and co-incidental bene-
fits. These include stronger immunization and surveil-
lance systems, well established global laboratory net-
work, millions of trained health workers and strong ad-
vocacy movements24,25. The option of controlling rather 
than eradicating polio (by means of routine immuniza-
tion only) has been shown in a modeling study to poten-
tially result in great cumulative cost and far larger num-




The prospects for polio eradication in Nigeria and by 
extension globally are high. These are based on: 
• The antecedent of not just small pox eradication but 
also progress so far made in polio eradication in 
Nigeria, India and the currently polio-free countries 
and regions. 
• The huge financial and human resources the country 
is able to mobilize from the Federal, State and Local 
Governments; as well as from International and 
local partners. 
• Already existing health care structure, especially for 
immunization, established by the National Pro-
gramme on Immunization (NPI) and improved upon 
by the National Healthcare Development Agency 
(NPHCDA). 
• High level of community and political awareness 
already achieved. 
• A level of political and community commitment 
• Skilled and experienced personnel-both full time 
and adhoc health workers. 
• Massive global technical, political and financial 
support especially based on the fact that polio eradi-





Although the prospects are high, the challenges are enor-
mous and require total commitment and focused strate-
gies to overcome. These challenges include; 
• Low and differential routine and supplemental im-
munization coverages below the threshold required 
for interruption of transmission. These immunity 
gaps allow viruses to persist in smaller areas and 
population sub-groups2. 
• Relatively lower effectiveness of tOPV resulting in 
low immunity especially against type 1 virus in 
vaccinated population15. Type 1 is the commonest 
in Nigeria. 
• The emergence of type 2 cVDPVs outbreaks in Ni-
geria whose transmissibility, pathogenicity   and 
disease severity are similar to those of type 2 WPV. 
Type 2 WPV has been eliminated globally since 
1999. 
• The continuing cases of VAPP resulting from the 
reverted VDPV.   
•   Mal-orientation of communities, politicians and 
health workers. 
• Politicization of health issues. 
• Very large population and high population growth 
rate with cultural, religious and geographical  
 barriers.  
• Funding short-falls and poor accountability frame-
work. 
 
With elimination of poliovirus in India, Nigeria stands 
out as the single most important country now in the 
global polio eradication agenda. 
 
The Way Forward 
 
• The current use of mOPV 1, mOPV 3, bOPV and 
tOPV must continue but must be guided by sound 
scientific advice from experts. However, the use of 
mOPV and bOPV must be balanced with the find-
ings of waning population immunity against type 2 
which predisposes to susceptibility to type 2 
cVDPV. Yet, it must be born in mind that tOPV 
which is the only OPV against type 2 has much 
lower effectiveness against the commonest type 1 in 
the country. This calls for a delicate balance in the
use of these vaccines and for further research. 
• It also draws the country’s attention towards plan-
ning to explore the place of IPV in the future which 
will totally eliminate the threat of cVDPVs and 
VAPP. 
• There is a very urgent need to raise routine immuni-
zation coverage to at least 95%. This coverage 
should not only be achieved nationally but also sub-
nationally in all Local Government Areas (LGAs) 
and wards. 
• Additionally SIAs should be more effective with 
realistic coverage approaching 100%.  
• Focused and effective mop up activities in special 
areas. 
• Continuing immunogenicity, epidemiological and 
communication studies are required to monitor 
trends and develop area-specific strategies. 
• Targeted mop ups and penetration of conflict areas 
are required to eliminate reservoirs of the virus. 
• Re-orientation of health workers, adhoc personnel, 
policy makers and the community.  
• Effective advocacy to politicians and massive social 
and community mobilization. 
• Targeted communication strategies aimed at over 
        coming cultural, religious and political barriers.             
 Also improvement in community participation  
• Intensive and special arrangement for adequate cov-
erage of hard to reach areas and migrant popula-
tions. 
• Urgent strengthening of AFP surveillance in all 
communities in all LGAs. 
• Country / government ownership of PEP as well as 
routine immunization programme with full imple-
mentation of the accountability framework. 
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Conclusion 
 
Small pox was eradicated and polio is biologically eradi-
cable. The global eradication effort has already achieved 
over 99% success with elimination certification in many 
countries and WHO regions. Even re-infections have 
been successfully and promptly eliminated in previously 
certified countries. India whose polio eradication history 
is similar to Nigeria’s in several ways has eventually 
achieved elimination certification. Nigeria has also 
achieved giant strides (90% success) since the PEP in 
the country. Therefore the prospects for polio eradica-
tion in Nigeria are high but the current challenges r -
quire urgent, sustained and focused attention so as to 
shorten the journey from now to eradication time. 
The future 
 
Even after WPV transmission is interrupted and elimi-
nated globally. The problem of reverted neurovirulent 
vaccine virus would remain to be addressed. As longas 
live OPV remains in use, Nigeria and indeed, the world 
cannot relax. Nigeria and the global community must 
plan for a switch from OPV to IPV and then complete 
stoppage of OPV production. Many countries have al-
ready stopped the use of OPV while others are at the 
OPV-IPV transition phase. While the call for a cheap r 
IPV continues, Nigeria must not wait but should begin 
to plan for financing of the switch. Local vaccine pro-
duction is a potentially cheaper option. 
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